Wound Dressings for Pemphigus and Pemphigoid
Launched by FUNDACIÓN NACIONAL PARA LA ENSEÑANZA Y LA INVESTIGACIÓN DE LA DERMATOLOGÍA A.C. · Feb 18, 2015
Trial Information
Current as of May 11, 2025
Unknown status
Keywords
ClinConnect Summary
Pemphigus and pemphigoid are the most frequently autoinmune bullous diseases seen in dermatology. Despite all the treatments that have been studied for the management of bullous skin diseases, there is insufficient information about the best skin dressing or cover that can be used in affected or denuded areas in these conditions.
Therefore we will compare the efficacy of four different covers (gauze with petrolatum , cellulose acetate with petrolatum , pure carboxymethylcellulose with silver and nanocrystalline silver) in providing faster healing and decreasing pain and itch.
Each patient...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of pemphigus vulgaris, pemphigus foliaceus , pemphigus vegetans, paraneoplastic pemphigus or bullous pemphigoid
- • At least four areas of active disease in the trunk or limbs of 8 x 8 cm characterized by denudation, ulceration, scabs or blisters.
- • Capable of being evaluated weekly either as outpatient or hospitalized
- • Actively treated with immunosuppressive or immunomodulatory drugs for pemphigus or pemphigoid control
- • Willing to sign an informed consent
- Exclusion Criteria:
- • Patients with hypersensitivity to any of the components of the skin dressings that will be used.
- • Patients who have participated in any clinical trial in the last 30 days.
About Fundación Nacional Para La Enseñanza Y La Investigación De La Dermatología A.C.
Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C. is a prominent clinical trial sponsor dedicated to advancing dermatological science through rigorous research and education. With a commitment to improving patient outcomes, the foundation fosters innovative studies that explore new treatments and therapies for skin disorders. By collaborating with leading healthcare professionals and institutions, it aims to enhance knowledge and practice in dermatology, ultimately contributing to better healthcare solutions and the dissemination of critical findings within the medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Mexico, Df, Mexico
Mexico, Df, Mexico
Patients applied
Trial Officials
Jose Contreras-Ruiz, MD
Principal Investigator
Hospital General Dr Manuel Gea Gonzalez
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials